News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (303 of 347). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 347). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (33 of 347). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 265 of 347 items have one.
Opinion: We think a baby’s gut microbiome could be key to lifelong brain health
“We need more rigorous, large-scale research into the gut-brain axis across the life course,” write Holly Baines and George Vradenburg.
May need a subscription The publisher's page marks this article as not free to read (checked 15 Oct 2026).
Read at STAT News → Archived copy (15 Oct 2026), Internet ArchiveSTAT+: Nobel-winning optogenetics research has led to experimental treatments for blindness and Alzheimer’s
Optogenetics is now the foundational way through which we are able to understand how the brain…
Why it matters: Optogenetics research has led to experimental treatments for blindness and Alzheimer's, serving as a foundational way to understand brain function.
May need a subscription Based on the outlet (STAT), not a check of this article.
Read at STAT News → Archived copy (5 Oct 2026), Internet ArchiveResearchers slow neurodegeneration in mice by barring T cells from the brain
A new study in mice led by Washington University in St. Louis researchers suggests that stopping certain immune cells from entering the brain could limit neurodegeneration.
Why it matters: Stopping certain immune cells from entering the brain could limit neurodegeneration, according to a study in mice led by Washington University in St. Louis researchers.
May need a subscription Based on the outlet (STAT), not a check of this article.
Read at STAT News → Archived copy (30 Sep 2026), Internet ArchiveHouse and Senate Appropriators Endorse NIH Budget Increase, Reject Trump's Proposed Cuts
Congressional appropriators set the NIH's overall budget at $48.7 billion for FY2026, a $415 million increase over FY2025, rejecting the White House's proposed cuts, while allowing a new multiyear-grant funding strategy to continue that had already resulted in thousands fewer awards to scientists in 2025.
Why it matters: Shows Congress broadly rebuffing proposed NIH cuts that had alarmed the Alzheimer's research community, though changes to multiyear grant funding could still constrain some researchers.
May need a subscription Based on the outlet (STAT), not a check of this article.
Read at STAT News → Archived copy (20 Jan 2026), Internet ArchiveJ&J's Novel Alzheimer's Drug Fails in Key Trial, Dimming Hopes for a Hot Target
Johnson & Johnson terminated its mid-stage trial of posdinemab, a tau-targeting antibody, after an early analysis showed it was not outperforming placebo in slowing Alzheimer's progression.
Why it matters: A setback for the broader strategy of targeting tau protein rather than amyloid, a drug class also being pursued by Biogen, UCB, and Voyager Therapeutics.
May need a subscription Based on the outlet (STAT), not a check of this article.
Read at STAT News → Archived copy (1 Mar 2026), Internet ArchiveCassava Sciences and Its Alzheimer's Drug Are Done. The Damage Lingers.
Cassava Sciences' simufilam failed both of its Phase 3 trials (RETHINK-ALZ and REFOCUS-ALZ) in nearly 2,000 patients, missing all co-primary, secondary, and biomarker endpoints; the company ended the program. The drug's development had been dogged by allegations of falsified research.
Why it matters: Closes out a controversial, years-long saga in Alzheimer's drug development and underscores the cost to patients and the field when research-integrity concerns aren't caught earlier.
May need a subscription Based on the outlet (STAT), not a check of this article.
Read at STAT News → Archived copy (30 May 2026), Internet ArchiveFollow new items in a feed reader: Atom feed.